Hypothesis

Combining a NAD+ precursor (NMN or NR) with low‑dose intermittent rapamycin (6 mg weekly) will produce synergistic increases in tissue NAD+ concentrations—particularly in brain and skeletal muscle—beyond what either agent achieves alone, and this metabolic enhancement will be reflected as a measurable slowing of DunedinPACE over a 3‑month interval.

Mechanistic Rationale

1. Complementary pathway activation: Rapamycin inhibits mTORC1, stimulating autophagy and NAD+‑consuming repair processes (e.g., PARP, sirtuins). Elevated NAD+ from precursors fuels these sirtuin‑dependent deacetylations, creating a feed‑forward loop that amplifies both autophagy flux and NAD+ recycling.
2. Gut‑mediated NA production: Both NMN and NR are converted by gut microbiota to nicotinic acid (NA), a potent NAD+ precursor that readily crosses the blood‑brain barrier. Rapamycin‑induced alterations in gut permeability and microbial composition may enhance this conversion, increasing NA delivery to peripheral tissues.
3. Tissue‑specific NAD+ pools: While blood NAD+ rises rapidly with precursors, tissue NAD+ lags due to limited transporter expression. Rapamycin upregulates nucleoside transporters (e.g., ENT1, CNT2) via FOXO3 activation, facilitating precursor uptake into brain and muscle.
4. Epigenetic clock sensitivity: DunedinPACE reflects the pace of physiological decline and has shown responsiveness to metabolic interventions over quarterly windows. A combined metabolic boost should reduce the rate of methylation change detectable within 3 months.

Testable Predictions

• Prediction 1: In a double‑blind, placebo‑controlled trial (n = 60, aged 50‑70), participants receiving NMN (250 mg BID) + rapamycin (6 mg weekly) will exhibit a ≥30 % greater increase in prefrontal cortex NAD+ (measured by MR spectroscopy) at week 12 compared with NMN alone or rapamycin alone (p < 0.01).
• Prediction 2: The same combination will produce a ≥15 % rise in muscle NAD+ (via biopsy LC‑MS) and a corresponding ↑ in autophagy markers (LC3‑II/I ratio, p62 degradation).
• Prediction 3: DunedinPACE will decline by ≥0.05 units (≈5 % slowing) in the combo group relative to placebo after 12 weeks, whereas monotherapy arms will show ≤0.02 change.
• Prediction 4: Fecal metabolite profiling will reveal a 2‑fold increase in NA levels in the combo group, correlating with tissue NAD+ gains (r > 0.5).

Falsifiability

If after 12 weeks the combo fails to show a statistically significant advantage over either monotherapy in tissue NAD+ elevation or DunedinPACE change, the hypothesis is refuted. Likewise, absence of increased fecal NA or transporter upregulation would undermine the proposed mechanistic chain.

Experimental Design (brief)

• Arms: Placebo, NMN alone, rapamycin alone, NMN + rapamycin.
• Duration: 12 weeks with dosing as described.
• Outcomes: MR spectroscopy brain NAD+, vastus lateralis muscle NAD+, autophagy immunoblots, fecal NA/qPCR for NAD+‑microbiota genes, DunedinPACE from blood methylome.
• Analysis: ANCOVA adjusting for baseline, with correction for multiple comparisons.

This framework directly tests whether synergistic metabolic modulation can translate into a quantifiable aging‑rate shift, addressing the current gap in combined NAD+ precursor and rapamycin research.